NCT01584440View on ClinicalTrials.gov

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

August 13, 2012

Primary Completion Date

July 30, 2014

Study Completion Date

July 30, 2014

Conditions
AgitationAlzheimer's Disease
Interventions
DRUG

AVP-923-20

AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine

DRUG

Placebo

Placebo capsule

DRUG

AVP-923-30

AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine

Trial Locations (44)

10605

White Plains

10962

Orangeburg

14620

Rochester

18104

Allentown

19604

Reading

29401

Charleston

32806

Orlando

33012

Hialeah

33064

Deerfield Beach

33122

Miami

33137

Miami

33173

Miami

33331

Weston

33351

Sunrise

33407

West Palm Beach

33409

West Palm Beach

33426

Boynton Beach

33609

Tampa

34471

Ocala

43221

Columbus

44107

Lakewood

44195

Cleveland

45227

Cincinnati

45459

Centerville

60007

Elk Grove Village

77030

Houston

78238

San Antonio

84106

Salt Lake City

85006

Phoenix

85351

Sun City

89106

Las Vegas

89147

Las Vegas

90073

Los Angeles

90095

Los Angeles

91403

Sherman Oaks

92103

San Diego

92591

Temecula

92835

Fullerton

93720

Fresno

94109

San Francisco

99204

Spokane

07902

Summit

08757

Toms River

05201

Bennington

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY

NCT01584440 - Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease | Biotech Hunter | Biotech Hunter